David Rind, ICER CMO
In draft report, ICER says Amylyx's ALS drug would not be cost effective if priced similarly to older treatment
Roughly 24 hours after Canadian regulators gave Amylyx Pharmaceuticals the thumbs-up for its new ALS drug, ICER is out with a new analysis trying to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.